文献速递乳腺MR

弥散加权MRI表现预测乳腺癌新辅助治疗病理缓解:ACRIN 6698多中心试验

Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.
PubMed 文献 · Radiology · 2018-09-04

这项前瞻性多中心研究纳入272例乳腺癌患者,在治疗前、治疗3周、12周及治疗后行乳腺弥散加权MRI,评估肿瘤表观弥散系数变化对病理完全缓解的预测价值。最终分析242例,其中80例(33%)达到病理完全缓解;治疗12周时ΔADC对病理完全缓解有中等预测能力(AUC=0.60),在HR阳性/HER2阴性亚型中预测能力较高(AUC=0.76)。

要点

  • 治疗12周时肿瘤ADC变化对病理完全缓解有中等预测价值(AUC=0.60)。
  • 治疗12周时ΔADC仅对HR阳性/HER2阴性亚型有预测价值(AUC=0.76)。
  • 联合肿瘤亚型与治疗12周ΔADC的模型预测性能优于单用ΔADC(AUC=0.72 vs 0.57)。

核心结论

  • 治疗12周后,乳腺肿瘤MRI表观弥散系数的变化可预测新辅助化疗的病理完全缓解。

研究设计与样本

  • 前瞻性多中心研究,10家机构连续纳入272例乳腺癌女性,2012年8月至2015年1月入组,随机接受12周每周紫杉醇(联合或不联合实验性药物)后接12周四个周期蒽环类治疗。

诊断标准与关键数值

  • 最终分析242例可评估连续影像数据,平均年龄48岁±10(标准差);HR阳性/HER2阴性99例,HR阴性/HER2阴性77例,HR阳性/HER2阳性42例,HR阴性/HER2阳性24例;80/242例(33%)发生病理完全缓解。

临床应用与阅片要点

  • 总体队列中,治疗12周时ΔADC预测病理完全缓解AUC=0.60(95%CI:0.52,0.68;P=.017),治疗后AUC=0.61(95%CI:0.52,0.69;P=.013)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To determine if the change in tumor apparent diffusion coefficient (ADC) at diffusion-weighted (DW) MRI is predictive of pathologic complete response (pCR) to neoadjuvant chemotherapy for breast cancer. Materials and Methods In this prospective multicenter study, 272 consecutive women with breast cancer were enrolled at 10 institutions (from August 2012 to January 2015) and were randomized to treatment with 12 weekly doses of paclitaxel (with or without an experimental agent), followed by 12 weeks of treatment with four cycles of anthracycline. Each woman underwent breast DW MRI before treatment, at early treatment (3 weeks), at midtreatment (12 weeks), and after treatment. Percentage change in tumor ADC from that before treatment (ΔADC) was measured at each time point. Performance for predicting pCR was assessed by using the area under the receiver operating characteristic curve (AUC) for the overall cohort and according to tumor hormone receptor (HR)/human epidermal growth factor receptor 2 (HER2) disease subtype. Results The final analysis included 242 patients with evaluable serial imaging data, with a mean age of 48 years ± 10 (standard deviation); 99 patients had HR-positive (hereafter, HR+)/HER2-negative (hereafter, HER2-) disease, 77 patients had HR-/HER2- disease, 42 patients had HR+/HER2+ disease, and 24 patients had HR-/HER2+ disease. Eighty (33%) of 242 patients experienced pCR. Overall, ΔADC was moderately predictive of pCR at midtreatment/12 weeks (AUC = 0.60; 95% confidence interval [CI]: 0.52, 0.68; P = .017) and after treatment (AUC = 0.61; 95% CI: 0.52, 0.69; P = .013). Across the four disease subtypes, midtreatment ΔADC was predictive only for HR+/HER2- tumors (AUC = 0.76; 95% CI: 0.62, 0.89; P < .001). In a test subset, a model combining tumor subtype and midtreatment ΔADC improved predictive performance (AUC = 0.72; 95% CI: 0.61, 0.83) over ΔADC alone (AUC = 0.57; 95% CI: 0.44, 0.70; P = .032.). Conclusion After 12 weeks of therapy, change in breast tumor apparent diffusion coefficient at MRI predicts complete pathologic response to neoadjuvant chemotherapy. © RSNA, 2018 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Partridge SC, Zhang Z, Newitt DC, et al. Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial. Radiology. 2018. PMID: 30179110. doi:10.1148/radiol.2018180273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。